AlzChem Group AG/€ACT
1D1W1MYTD1Y5YMAX
Capital at risk
About AlzChem Group AG
AlzChem Group AG operates within the chemical industry, focusing on the production and distribution of specialty chemicals. The company offers a wide range of products, including nitrile and guanidine derivatives, which are used in various applications such as agriculture, pharmaceuticals, and renewable energy. Headquartered in Trostberg, Germany, AlzChem has a strong foundation in the region but exports its products globally. The company's strategic positioning leverages its specialized product offerings and research capabilities, enabling it to serve niche markets with high-value solutions. AlzChem's history includes a rich legacy of chemical expertise and innovation that began at its founding.
- Ticker
- €ACT
- Sector
- Materials
- Primary listing
- XETRA
- Employees
- 1,680
- Headquarters
- Trostberg, Germany
- Website
- www.alzchem.com
AlzChem Group AG Metrics
BasicAdvanced
€1.6B
23.98
€6.70
0.39
€2.10
1.31%
Price and volume
Market cap
€1.6B
Beta
0.39
52-week high
€209.40
52-week low
€122.60
Average daily volume
22K
Dividend rate
€2.10
Financial strength
Current ratio
2.704
Quick ratio
1.739
Long term debt to equity
30.186
Total debt to equity
33.18
Dividend payout ratio (TTM)
31.37%
Interest coverage (TTM)
44.77%
Profitability
EBITDA (TTM)
118.133
Gross margin (TTM)
65.63%
Net profit margin (TTM)
11.41%
Operating margin (TTM)
15.70%
Effective tax rate (TTM)
27.42%
Revenue per employee (TTM)
€350,000
Management effectiveness
Return on assets (TTM)
9.50%
Return on equity (TTM)
27.66%
Valuation
Price to earnings (TTM)
23.982
Price to revenue (TTM)
2.737
Price to book
6.02
Price to tangible book (TTM)
6.1
Price to free cash flow (TTM)
-73.609
Free cash flow yield (TTM)
-1.36%
Free cash flow per share (TTM)
-2.183
Dividend yield (TTM)
1.31%
Forward dividend yield
1.31%
Growth
Revenue change (TTM)
5.50%
Earnings per share change (TTM)
17.31%
3-year revenue growth (CAGR)
2.31%
3-year earnings per share growth (CAGR)
35.05%
3-year dividend per share growth (CAGR)
25.99%
Bulls say / Bears say
Group EBITDA rose 10% year-on-year to €27.4 million in Q1 2026, reflecting strong margin expansion in specialty chemicals (Reuters)
Alzchem reported record FY 2025 group sales of €562.1 million, driven by its high-value specialty chemicals business (Reuters)
Management reaffirmed its full-year 2026 outlook for continued sales and EBITDA growth, underscoring confidence in its growth trajectory (Reuters)
Adoption of a €120 million investment program for an automated creatine production facility ties up significant capital with returns deferred until plant commissioning later on (Reuters)
Alzchem’s decision to temporarily interrupt its share buyback program from April 30 to May 8, 2026 may reduce near-term support for the stock and dampen investor sentiment (Reuters)
Extension of CEO Andreas Niedermaier’s and CFO Andreas Lösler’s contracts ahead of schedule could entrench existing management strategy and limit fresh governance perspectives (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 26 Aug 2026.
Upcoming events
No upcoming events
Funds containing AlzChem Group AG
AllEURGBPUSD
Fund name | Fund size | €ACT weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.08% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.08% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
iShares MSCI World Small Cap£WLDS | £6.7B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.